Dengue virus pre-membrane protein and envelope protein (prM and E (or prM/E))

The **Dengue virus pre-membrane protein (prM)** and **envelope protein (E)** are the two main surface structural proteins present on immature DENV particles. **prM** acts as a chaperone during viral assembly, capping the fusion loop of the E protein to prevent premature membrane fusion; upon maturation, prM is cleaved to "M," allowing E to mediate fusion. The **envelope protein (E)** is a class II viral fusion glycoprotein essential for viral attachment to host cells, receptor binding, antigenicity, and pH-triggered membrane fusion, enabling viral genome entry into the host cytoplasm. The E protein comprises three domains (DI, DII, DIII), where DIII is implicated in receptor binding and DII in fusion via a hydrophobic loop exposed in acidic endosomal conditions; these dynamic conformational changes are fundamental to DENV infectivity. Both **prM** and **E** are critical targets for immune responses, antiviral drug development, and vaccine strategies, but present challenges including the risk of ADE and serotype cross-reactivity. Experimental inhibitors (such as pentagalloylglucose) and neutralizing antibodies are under investigation as therapeutics focusing on these proteins.

Other names

DENV prM and E proteinsDengue virus prM and EPremembrane protein (prM)Envelope protein (E)DENV E glycoprotein

Inhibition of viral entry: Small molecules or antibodies block E protein-mediated attachment or membrane fusion Immunoneutralization: Antibodies bind to E protein quaternary or domain epitopes, preventing viral entry and infection Virus maturation inhibition: Molecules or antibodies targeting prM-E complex interfere with the structural rearrangement essential for infectivity